Please login to the form below

Not currently logged in
Email:
Password:

Oxford Cancer Biomarkers

This page shows the latest Oxford Cancer Biomarkers news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca expands personalised drug partnership with Horizon

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments. AstraZeneca (AZ) has signed a deal with UK genomics company Horizon Discovery to research genetic drug targets for personalised cancer treatments. ... Other recent oncology agreements

Latest news

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    These other deals include the acquisition of cancer specialist Amplimmune and US biotech AlphaCore Pharma; the acquisition of a drug developed by FibroGen for anaemia associated with chronic kidney disease; and ... AZ has also entered research

  • AZ adds to pipeline again with Amplimmune buy AZ adds to pipeline again with Amplimmune buy

    It will allow us to strengthen our arsenal of potential cancer therapies," he added. ... Added to that haul have been collaborations with Moderna Therapeutics, the Karolinska Institutet and Oxford Cancer Biomarkers, as well as a $200m licence agreement

  • AZ inks $815m deal for FibroGen anaemia drug AZ inks $815m deal for FibroGen anaemia drug

    Most recently the firm snapped up respiratory specialist Pearl Therapeutics in a deal valued at up to $1.15bn, having previously forged collaborations with Moderna Therapeutics, the Karolinska Institutet and Oxford ... Cancer Biomarkers, as well as a

  • AstraZeneca and NGM form diabetes/ obesity partnership AstraZeneca and NGM form diabetes/ obesity partnership

    These deals include the acquisition of Pearl Therapuetics, Omthera Pharmaceuticals and AlphaCore Pharma, as well as collaboration agreements with Moderna Therapuetics and Oxford Cancer Biomarkers.

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    These deals include collaboration agreements with Moderna Therapeutics, the Karolinska Institutet and Oxford Cancer Biomarkers, as well as a licence agreement with Bind Therapeutics and the purchase of US biotechs AlphaCore

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer. ... Critical to that thinking is keeping track of the latest developments in technology and working with companies, such as Oxford Cancer Biomarkers,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics